Skip to main content
. 2021 Nov 16;13(22):5744. doi: 10.3390/cancers13225744

Figure 2.

Figure 2

UAMC-1110, developed at the University of Antwerp, and various FAPI-tracers, developed by the Haberkorn group, based on this motif. FAPI-04 was the first theragnostic anti-FAP agent and is currently the most investigated tracer. FAPI-46 offers improved tumor retention and pharmacokinetics; FAPI-74 can be labeled with [18F]aluminum fluoride or 68Ga at ambient temperature; FAPI-34 is suitable for labeling with the theragnostic pair 99mTc/186/188Re.